AstraZeneca (LON:AZN) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Key Points

• AstraZeneca shares have surpassed their 200-day moving average, trading at £110.54 ($147.66) after reaching a high of £112.74 ($150.60).
• Brokerage firms have mixed ratings for the stock, with Deutsche Bank holding a "hold" rating while Shore Capital and Berenberg Bank maintain "buy" ratings with price targets of £135 ($180.34) and GBX 140 ($1.87), respectively.
• The company has a significant market capitalization of £209.57 billion and a current ratio of 0.93, indicating its liquidity position.

AstraZeneca PLC (LON:AZN - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of £108.85 ($146.35) and traded as high as £112.74 ($151.57). AstraZeneca shares last traded at £110.54 ($148.62), with a volume of 1,452,037 shares trading hands.

Analyst Ratings Changes

Several research firms have weighed in on AZN. Shore Capital reiterated a "buy" rating and set a £135 ($181.50) price target on shares of AstraZeneca in a research note on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a £110 ($147.89) price target on shares of AstraZeneca in a research note on Wednesday, July 30th. Finally, Berenberg Bank restated a "buy" rating and issued a GBX 140 ($1.88) target price on shares of AstraZeneca in a research note on Friday, May 16th.

AstraZeneca Stock Up 1.2%

The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The stock has a market cap of £212.65 billion, a PE ratio of 30.30, a P/E/G ratio of 0.86 and a beta of 0.17. The business has a 50 day moving average price of £106.38 and a 200 day moving average price of £108.85.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.